ResMed Inc. announced the election of Nicole Mowad-Nassar to its board of directors, effective August 15, 2025. The company also announced that board member Rich Sulpizio will retire from the board, not standing for reelection at the 2025 Annual Meeting of Stockholders, scheduled for November 19, 2025. Nicole Mowad-Nassar currently serves as President of Specialty and U.S. Therapeutics Operations at AbbVie.
She leads a $6 billion commercial portfolio spanning more than 17 therapeutic areas and oversees a workforce of 6,000. Over her 30-year career, she has held senior executive roles across commercial strategy, marketing, digital innovation, patient services, and large-scale business transformation. Her leadership includes both U.S. and global responsibilities, with direct contributions to long-range strategic planning, digital health innovation, and enterprise integration.
At AbbVie, Mowad-Nassar led the commercial integration of the $63 billion Allergan acquisition, one of the largest in industry history. She ensured continuity across product launches, while minimizing operational disruption. Mowad-Nassar will serve as an independent director and has been appointed to the Compensation and Leadership Development Committee.
She will stand for reelection with the rest of Resmed?s board members at the company?s 2025 Annual Meeting of Stockholders. Rich Sulpizio, who has served on Resmed?s board of directors since 2005, will retire following the 2025 Annual Meeting. During his tenure, Rich has chaired the Compensation Committee, served on the Audit Committee, and most recently chaired the Nominating and Governance committee.
Sulpizio is the former President and Chief Operating Officer of Qualcomm, and served on the board of both Qualcomm and CA Technologies.
